Granite Point Capital Management, L.P. Prothena Corp Public LTD CO Transaction History

Granite Point Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 13, 2018	SELL	$10.99 - $44.21 $272,552 - $1.1 Million	-24,800 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$27.95 - $45.04 $145,340 - $234,208	-5,200 Reduced 17.33%	24,800 $910,000
Q4 2017 Feb 08, 2018	BUY	$35.44 - $63.76 $1.06 Million - $1.91 Million	30,000	30,000 $1.13 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $685M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.